Purpose: This study aimed to investigate the level of salivary endothelin-1 in premalignant and malignant lesions.
Materials and methods: In this study, 75 cases were investigated of which 25 cases were healthy, 25 cases had oral lichen planus (OLP), and 25 cases had oral squamous cell carcinoma (OSCC). In order to collect the saliva samples, the unstimulated spitting was used. The samples were collected between 9 and 12 a.m. They were sent to the lab shortly after being collected and salivary endothelin-1 was recorded for each sample according to the instruction of factory by using enzyme-linked immunosorbent assay and optical density at a wavelength of 450 nm. SPSS version 20 and one-way ANOVA and LSD tests were used to analyze the data.
Results: The mean of salivary endothelin-1 level in patients with OSCC was 163.98 pg/ml, in patients with OLP was 160.9 pg/ml, and in healthy people was 137.19 pg/ml. The analysis of one-way ANOVA suggested that the level of salivary endothelin-1 in both groups was the same and significantly higher than that in control group (p < 0.05).
Conclusions: The level of salivary endothelin-1 in patients with SCC and OLP was higher than that in healthy group. Thus, it can be used as the latest therapeutic protocol for oral premalignant and malignant lesions.
Keywords: SCC; oral lichen planus; salivary endothelin-1.
© 2017 Special Care Dentistry Association and Wiley Periodicals, Inc.